Anti-estrogen and immune modulator combinations for treating breast cancer
First Claim
1. A method of predicting susceptibility of a cancer of mucosal origin to treatment with an immunoglobulin inhibitor mimicking compound, the method comprising:
- identifying in a specimen of said cancer cells expression of a Poly-Ig (Fc) receptor or a Poly-Ig-like (Fc) receptor that is capable of binding to said immunoglobulin inhibitor mimicking compound and of mediating immunoglobulin inhibition of cancer cell growth in cancer cells of mucosal origin.
0 Assignments
0 Petitions
Accused Products
Abstract
Compositions for treating cancers of mucosal tissues including breast, prostate, ovary, colon are disclosed which include various combinations of new or conventional anti-estrogen compounds, aromatase inhibitors, immune modulators, immune inhibitors, immune inhibitor mimicking compounds and steroid or thyroid hormones. Methods of predicting susceptibility of a cancer of mucosal origin to treatment with a composition containing an immune inhibitor or an immune inhibitor mimicking compound are also disclosed. Preferred methods include identifying in a specimen of cancer cells the presence of a Poly-Ig (Fc) receptor or Poly-Ig-like (Fc) receptor capable of binding to an immune inhibitor or an immune inhibitor mimicking compound and of mediating immune inhibition of cancer cell growth.
-
Citations
28 Claims
-
1. A method of predicting susceptibility of a cancer of mucosal origin to treatment with an immunoglobulin inhibitor mimicking compound, the method comprising:
- identifying in a specimen of said cancer cells expression of a Poly-Ig (Fc) receptor or a Poly-Ig-like (Fc) receptor that is capable of binding to said immunoglobulin inhibitor mimicking compound and of mediating immunoglobulin inhibition of cancer cell growth in cancer cells of mucosal origin.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
9. A method of treating breast cancer in an individual in need of such treatment, the method comprising:
-
in a specimen of breast cancer cells from said individual, determining susceptibility of at least a portion of said cells to cell growth inhibition by an immunoglobulin inhibitor mimicking compound by a method comprising identifying in at least a portion of said cells the expression of a Poly-Ig receptor or Poly-Ig-like receptor, or the Fc receptor region thereof, that is capable of binding to said immunoglobulin inhibitor mimicking compound and mediating immunoglobulin inhibition of breast cancer cell growth; and
administering said immunoglobulin inhibitor mimicking compound to said individual. - View Dependent Claims (10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 25, 26, 27)
-
-
22. A pharmaceutical composition for treating a cancer of mucosal origin comprising:
-
an immune inhibitor of steroid hormone reversible cancer cell growth or an immune inhibitor mimicking compound; and
at least one at least one component chosen from the group consisting of;
an anti-estrogen compound, an aromatase inhibitor, an agent that enhances immunoglobulin production, and a hormone, together with a pharmaceutically acceptable carrier. - View Dependent Claims (23, 24)
-
-
28. A method of screening a compound for anti-estrogenic activity comprising:
-
culturing a predetermined population of estrogen responsive cancer cells in a nutrient medium comprising a quantity of immunoglobulin inhibitor or immunoglobulin inhibitor mimicking compound sufficient to inhibit cell growth in the absence of an inhibition-reversing amount of estrogen;
adding a defined amount of the substance of interest to the cell culture medium;
adding a defined amount of estrogen to said cell culture medium, said amount being sufficient to stimulate cell growth in the presence of said inhibitor or inhibitor mimicking agent under the same cell culture conditions but in the absence of said substance of interest, to provide a test culture;
incubating said test culture for a predetermined period of time under growth promoting conditions;
testing said substance of interest for cytotoxic effects on said cells;
determining the cell population of the test culture after said predetermined period of time, wherein a lack of increase in the cell population, not attributable to cytotoxic effects of said substance of interest, indicates an anti-estrogenic effect by said substance of interest.
-
Specification